{"id":"skp-fluticasone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Oropharyngeal candidiasis"},{"rate":"5-10","effect":"Dysphonia / hoarseness"},{"rate":"1-5","effect":"Tremor"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Throat irritation"}]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone is a potent inhaled corticosteroid that works by activating glucocorticoid receptors in immune cells, leading to decreased production of inflammatory mediators and reduced airway inflammation. SKP-Fluticasone represents a formulation or delivery optimization of the established fluticasone molecule by SkyePharma AG, likely designed to improve bioavailability, lung deposition, or patient convenience.","oneSentence":"SKP-Fluticasone is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing immune and inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:07.332Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (likely maintenance therapy)"},{"name":"Chronic obstructive pulmonary disease (COPD) (likely)"}]},"trialDetails":[{"nctId":"NCT00393991","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-07","conditions":"Asthma","enrollment":475},{"nctId":"NCT00394199","phase":"PHASE3","title":"Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":357},{"nctId":"NCT00747318","phase":"PHASE3","title":"A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Asthma","enrollment":280},{"nctId":"NCT00393952","phase":"PHASE3","title":"New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2006-06","conditions":"Asthma","enrollment":557},{"nctId":"NCT00649025","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-03","conditions":"Asthma","enrollment":438},{"nctId":"NCT00734292","phase":"PHASE2","title":"Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Mild to Moderate Asthma","enrollment":39},{"nctId":"NCT00657774","phase":"PHASE1","title":"A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-04","conditions":"Asthma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SKP-Fluticasone","genericName":"SKP-Fluticasone","companyName":"SkyePharma AG","companyId":"skyepharma-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SKP-Fluticasone is a glucocorticoid receptor agonist, classified as an AGONIST, and is used to treat Asthma and Mild to Moderate Asthma. It is a small molecule that acts as a glucocorticoid receptor agonist, similar to other drugs such as Fluticasone propionate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}